Breaking Research News Today

Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures...

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

LOS ANGELES--(BUSINESS WIRE)--Mar 12, 2024--

Apple's CEO Tim Cook announces a major expansion in AI, launching a global hiring spree to develop cutting-edge generative AI tools, with a $22.61 billion investment in R&D.

Company to share preclinical data on the use of integrated circuit T cells for the development of cell therapies for the treatment of kidney and other solid tumor cancersSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#AACR23--Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company e...

Study data shows consistent independent risk stratification performance of DecisionDx-SCC in a novel cohort of patients with cutaneous squamous cell carcinoma and one or more risk factors ... | March 18, 2023

- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented -- Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed -- Preclinical data and discovery research underscore Seagen’s mission to innovate through next-gener...

Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)

Use of ruxolitinib cream (Opzelura) resulted in further improvement in facial and total body repigmentation at Week 52 Results will be featured as an oral presentation in a late-breaking abstract session

New data on ruxolitinib cream (Opzelura) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking